{"denoms":[{"counts":[{"groupId":"BG000","value":"50"}],"units":"Participants"}],"groups":[{"description":"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.\n\nCONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.\n\nTreatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nfilgrastim: Given SC\n\nclofarabine: Given IV\n\ncytarabine: Given IV","id":"BG000","title":"Treatment (Chemotherapy and Colony Stimulating Factor)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"64","value":"53"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Favorable"},{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Intermediate"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Unfavorable"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Indeterminate"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Cytogenetic Risk Factor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Antecedent hematological disorder (AHD)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}]}],"description":"Number of participants with a FLT3 ITD mutation","paramType":"COUNT_OF_PARTICIPANTS","title":"FLT3 ITD mutation status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.8","upperLimit":"761.3","value":"12"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"WBC","unitOfMeasure":"cells x 10^9/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"100","value":"16"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Peripheral Blast","unitOfMeasure":"percent of white blood cells"}]}